.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,181,257

« Back to Dashboard

Claims for Patent: 9,181,257

Title:Inhibitors of Bruton's tyrosine kinase
Abstract: Disclosed herein are pyrazolo[3,4-d]pyrimidines that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s): Honigberg; Lee (San Francisco, CA), Verner; Erik (Belmont, CA), Pan; Zhengying (Austin, TX)
Assignee: PHARMACYCLICS LLC (Sunnyvale, CA)
Application Number:14/080,640
Patent Claims: 1. A compound of Formula (A) having the structure: ##STR00057## wherein: A is N; R.sub.1 is L.sub.2-(substituted or unsubstituted heteroaryl), or L.sub.2-(substituted or unsubstituted aryl), where L.sub.2 is a bond, O, S, --S(.dbd.O), --S(.dbd.O).sub.2, C(.dbd.O), -(substituted or unsubstituted C.sub.1-C.sub.6 alkyl), or -(substituted or unsubstituted C.sub.2-C.sub.6 alkenyl); R.sub.2 and R.sub.3 are independently selected from H or lower alkyl; R.sub.4 is L.sub.3-X-L.sub.4-G, wherein, L.sub.3 is optional, and when present is a bond, or an optionally substituted or unsubstituted alkyl; X is a bond; L.sub.4 is a substituted or unsubstituted nitrogen containing heterocycle; or L.sub.3, X and L.sub.4 taken together form a nitrogen containing heterocyclic ring; and G is a Michael acceptor moiety; or a pharmaceutically acceptable solvate, hydrate, or salt thereof.

2. The compound of claim 1, wherein G is bound to a nitrogen atom in L.sub.4.

3. The compound of claim 2, wherein G is bound to a nitrogen atom in L.sub.4 to form a substituted acrylamide.

4. The compound of claim 3, wherein R.sub.1 is L.sub.2-substituted aryl; and L.sub.2 is a bond.

5. The compound of claim 4, wherein R.sub.2 and R.sub.3 are independently H.

6. The compound of claim 5, wherein L.sub.3 is optionally substituted or unsubstituted alkyl.

7. The compound of claim 6, wherein L.sub.3 is methylene and L.sub.4 is pyrrolidine or piperidine.

8. The compound of claim 5, wherein the compound of Formula (A) has the structure of Formula (B): ##STR00058## wherein: Y and R.sub.12 taken together form a 4-, 5-, or 6-membered heterocyclic ring; each R.sub.a is independently H, halogen, --CF.sub.3, --CN, --NO.sub.2, OH, NH.sub.2, -L.sub.a-(substituted or unsubstituted alkyl), -L.sub.a-(substituted or unsubstituted alkenyl), -L.sub.a-(substituted or unsubstituted heteroaryl), or -L.sub.a-(substituted or unsubstituted aryl), wherein L.sub.a is a bond, O, S, --S(.dbd.O), --S(.dbd.O).sub.2, NH, C(O), CH.sub.2, --NHC(O)O, --NHC(O), or --C(O)NH; and G together with the nitrogen atom to which it is bound forms a substituted acrylamide; or a pharmaceutically acceptable solvate, hydrate, or salt thereof.

9. The compound of claim 8, wherein each R.sub.a is independently H, halogen, -L.sub.a-(substituted or unsubstituted heteroaryl), or -L.sub.a-(substituted or unsubstituted aryl), wherein L.sub.a is O, --NHC(O), or --C(O)NH.

10. The compound of claim 9, wherein each R.sub.a is independently H, F, or -L.sub.a-(substituted or unsubstituted aryl), wherein L.sub.a is O.

11. The compound of claim 10, wherein one R.sub.a is F, and one R.sub.a is --O-(unsubstituted phenyl).

12. The compound of claim 10, wherein one R.sub.a is --O-(substituted phenyl) and --O-(substituted phenyl) is substituted with one or more F.

13. The compound of claim 8, wherein Y and R.sub.12 taken together form a piperidine ring.

14. The compound of claim 8, wherein Y and R.sub.12 taken together form a pyrrolidine ring.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc